Charles River Laboratories International Inc. stock outperforms competitors on strong trading day
Charles River Laboratories International Inc. (CRL) stock advanced 1.81% to $158.86, outpacing the broader market on a strong trading day. The S&P 500 Index rose 0.17% and the Dow Jones Industrial Average gained 0.55%. This marked the third consecutive day of gains for Charles River Laboratories.
Q1 Earnings Recap: West Pharmaceutical Services (NYSE:WST) Tops Drug Development Inputs & Services Stocks
West Pharmaceutical Services (NYSE:WST) led the drug development inputs & services industry in Q1, reporting strong revenues of $844.9 million, up 21% year-on-year, and exceeding analyst expectations. The company attributed its success to continued market demand and increased production, particularly in Europe, and subsequently raised its full-year 2026 guidance. While the broader drug development inputs & services sector saw a collective decline in share prices despite revenues beating estimates, West Pharmaceutical Services and Fortrea (NASDAQ:FTRE) showed significant stock increases post-earnings, with Azenta (NASDAQ:AZTA) and Charles River Laboratories (NYSE:CRL) facing declines.
Should Higher Impairments and AI Investments Shape a New Capital Allocation Playbook for Charles River (CRL)?
Charles River Laboratories (CRL) reported first-quarter results showing modest revenue growth but a net loss and increased impairments, alongside a raised full-year GAAP EPS guidance. The company is actively reshaping its business through significant investments in AI-enabled digital pathology and cell therapy testing collaborations, aiming for improved efficiency and margin recovery. While these strategic shifts indicate a focus on higher-value services, investors are encouraged to consider the impact of rising cancellations and a book-to-bill ratio below 1x on the benefits of these initiatives.
Should Higher Impairments and AI Investments Shape a New Capital Allocation Playbook for Charles River (CRL)?
Charles River Laboratories reported mixed Q1 2026 results with a net loss and higher impairments but raised full-year GAAP EPS guidance and continued investments in AI-enabled digital pathology and cell therapy testing. The company aims to improve margins through productivity gains and complex biologics work, with a fair value estimate of $215.73, suggesting a 38% upside despite ongoing challenges like rising cancellations. The article suggests focusing on the company's shift towards higher-value services to offset pressures on traditional animal-based research.
Q1 Earnings Recap: West Pharmaceutical Services (NYSE:WST) Tops Drug Development Inputs & Services Stocks
West Pharmaceutical Services (NYSE:WST) reported a strong Q1, significantly exceeding revenue and adjusted EPS expectations with 21% year-on-year revenue growth. The company raised its full-year 2026 guidance, driven by robust demand for its High Value Products Components business. Fortrea (NASDAQ:FTRE) also had a strong quarter, beating EPS and revenue estimates, while Azenta (NASDAQ:AZTA) delivered the weakest performance against analyst estimates, with revenues falling short of expectations.
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day
Charles River Laboratories International Inc. (CRL) saw its stock rise by 2.36% to $156.03 on Wednesday, outperforming the broader market. This gain occurred during a strong trading session where the S&P 500 Index increased by 1.08% and the Dow Jones Industrial Average rose by 1.31%. This marks the second consecutive day of gains for the company's stock.
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day
Charles River Laboratories International Inc. (CRL) saw its stock rally by 1.67% to $152.43 on Tuesday, outperforming the broader market which experienced a downturn. This rise broke a four-day losing streak for the company's shares. The S&P 500 Index and Dow Jones Industrial Average both fell on the same trading day.
A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness
Charles River Laboratories International (CRL) has seen its stock price decline significantly in recent months, prompting a re-evaluation of its valuation. While one narrative suggests the stock is 52.2% undervalued with a fair value of $313.61, indicating a long-term opportunity, a Discounted Cash Flow (DCF) model from Simply Wall St points to an overvalued stock with an estimated value of $78.12. Investors are encouraged to review both perspectives and consider the associated risks and opportunities before making investment decisions.
A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness
Charles River Laboratories International (CRL) has seen its stock price drop by 18% in the past month, leading to questions about its valuation. While one narrative suggests the company is 52.2% undervalued with a fair value of $313.61, indicating fresh interest, Simply Wall St's DCF model calculates a fair value of $78.12, presenting a significant discrepancy. Investors are encouraged to review both perspectives and assess inherent risks, particularly concerning regulatory scrutiny of primate sourcing.
Inspired Announces CFO Transition
Inspired Entertainment, Inc. announced a CFO transition, with James Richardson stepping down and Craig Wilson promoted to Executive Vice President and Chief Financial Officer, effective May 14, 2026. Wilson, who joined Inspired in 2025, previously held leadership roles at Charles River Laboratories International, Inc. and Walgreens Boots Alliance. He will bring extensive experience in U.S. GAAP, financial reporting, forecasting, and planning to his new role.
Charles River Deepens Cell Therapy Role And Expands AI Pathology Platform
Charles River Laboratories International (NYSE:CRL) has partnered with MEDIPOST to expand its cell therapy development and commercialization services across Asia-Pacific and North America, providing biologics and GMP testing. Concurrently, Charles River has significantly upgraded its digital pathology platform with AI-powered workflows to enhance study timelines, quality control, and reduce animal testing. These strategic moves position Charles River at the forefront of cell therapy and digital research, adapting to evolving industry needs.
Charles River Deepens Cell Therapy Role And Expands AI Pathology Platform
Charles River Laboratories International (NYSE:CRL) has partnered with MEDIPOST to advance cell therapy development and commercialization in North America and Asia-Pacific, while also upgrading its digital pathology platform with AI-powered capabilities. These moves aim to streamline research, improve efficiency, and support the growing cell and gene therapy sector. Investors should monitor the conversion of the MEDIPOST MOU into testing volumes and the progress of the digital pathology advancements.
Charles River Laboratories Tops Q3 Estimates, Tightens Full-Year Outlook
Charles River Laboratories (CRL) exceeded third-quarter revenue and earnings estimates. The company reported a 10.6% increase in net sales and a 9.5% rise in non-GAAP earnings per share, driven by strong growth in its Research Models and Services (RMS) and Manufacturing segments, despite a slight decline in its Discovery and Safety Assessment (DSA) segment. Charles River also adjusted its full-year 2024 guidance, narrowing its revenue growth and non-GAAP EPS expectations.
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors
Shares of Charles River Laboratories International Inc. (CRL) fell 5.20% on Friday, closing at $150.85. This underperformance occurred during a generally dismal trading session, with the S&P 500 Index and Dow Jones Industrial Average also experiencing declines. This marked the third consecutive day of losses for the stock.
Charles River Deepens Cell Therapy Role And Expands AI Pathology Platform
Charles River Laboratories, International (NYSE:CRL) has partnered with MEDIPOST to expand its cell therapy services across Asia-Pacific and North America, offering biologics and GMP testing. Concurrently, Charles River has upgraded its digital pathology platform with AI-powered workflows to enhance research efficiency and animal reduction. These strategic moves underline Charles River's focus on advanced cell therapy pipelines and automated research tools, positioning it in specialized testing and data-rich workflows within the contract research organization sector.
Director Nancy Andrews gifts Charles River (CRL) shares to trust
Charles River Laboratories International, Inc. director Nancy C. Andrews reported gifting a total of 7,928 shares of common stock on May 12, 2026. The shares were transferred in two transactions of 3,964 shares each, with one transfer moving shares to a revocable trust she controls, reallocating her holdings from direct to indirect ownership. These were bona fide gifts and not open-market sales.
Evotec SE stock (DE0005664809): Drug discovery leader eyes US biotech growth
Evotec SE, a German drug discovery leader, is strategically advancing partnerships with major US pharmaceutical companies, making it a significant player for American biotech investors. The company's core business model focuses on industrialized drug discovery and development, integrating AI-driven technologies and collaborating with pharma and biotech firms to de-risk R&D. With approximately 50% of its revenue from North American collaborations, Evotec's strong presence in the US market and its resilient partnership model are key to its growth.
Charles River Laboratories stock (US1591881009): Q1 earnings beat with updated FY guidance
Charles River Laboratories (CRL) reported a strong Q1 2026, exceeding revenue and EPS estimates and updating its full-year guidance for 2026. Despite the positive results, the stock remained flat post-announcement. The company, a key player in the life sciences sector, provides essential research and drug development services globally, with a significant client base in North America.
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors
Shares of Charles River Laboratories International Inc. (CRL) fell 2.29% on Thursday, closing at $159.12. This underperformance occurred on a generally positive day for the stock market, with both the S&P 500 Index and the Dow Jones Industrial Average seeing gains. This marks the second consecutive day of losses for the company's stock.
Simplify Health Care ETF (NY: PINK)
This article provides detailed stock information for the Simplify Health Care ETF (NYSE: PINK), including its current trading price, volume, range, and dividend yield. It also lists recent news headlines related to various companies, focusing on financial results, mergers, and other corporate announcements. The article concludes with frequently asked questions about the ETF's trading status, exchange, ticker symbol, and market capitalization.
Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions
Charles River Laboratories and MEDIPOST Co., Ltd. have signed a non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing and commercial/marketing efforts for cell therapy development. This partnership leverages Charles River's expertise in biologics and cell therapy GMP testing to support MEDIPOST's global cell therapy pipeline, initially focusing on the Asia-Pacific and North America regions. The collaboration aims to accelerate access to safe and effective cell therapies by providing specialized quality control, viral testing, and release testing services.
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors
Charles River Laboratories International Inc. (CRL) stock fell 3.46% on Wednesday, closing at $162.85. This performance lagged behind the broader market, with the S&P 500 Index rising and the Dow Jones Industrial Average slightly decreasing. The company's stock is currently 28.85% below its 52-week high.
ICON's New Texas Hub Aims to Reshape Early Phase Drug Trials
ICON plc has expanded its U.S. operations with a new Clinical Research Unit in San Antonio and satellite clinics, aiming to accelerate early-phase drug trials. This strategic move responds to the growing CRO market and increasing R&D spending, integrating clinical, laboratory, and pharmacy operations to enhance efficiency, reduce delays, and improve data quality. The expansion also focuses on patient-centric design and recruitment diversification, positioning ICON as a leader in pharmaceutical development and bolstering San Antonio's life sciences sector.
Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions
Charles River Laboratories and MEDIPOST Co., Ltd. have signed a non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing and commercial/marketing efforts for cell therapy development. This partnership aims to leverage Charles River's expertise in biologics and cell therapy GMP testing to support MEDIPOST's global cell therapy pipeline, initially focusing on the Asia-Pacific and North America regions. The collaboration seeks to accelerate access to safe and effective cell therapies, particularly within the APAC region, by providing specialized expertise and efficient development pathways.
New Charles River–MEDIPOST deal targets safer cell therapies worldwide
Charles River Laboratories and MEDIPOST Co., Ltd. have signed a non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing and commercial/marketing efforts for cell therapy development. This partnership aims to advance safe and compliant cell therapy products globally, leveraging Charles River's expertise in biologics and cell therapy GMP testing to support MEDIPOST's expansion from South Korea to APAC, North America, the Middle East, and Europe. MEDIPOST, known for its commercial-stage allogeneic cell therapy product CARTISTEM®, will benefit from Charles River's quality control, viral testing, and release testing services to navigate various regulatory jurisdictions.
[Form 4] CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Insider Trading Activity
Charles River Laboratories International, Inc. director Steven Barg reported an equity award of 1,438 shares of Common Stock on May 8, 2026. This grant, valued at $177.62 per share, is not an open-market purchase but compensation, with the restricted stock units vesting by May 8, 2027, or the business day before the next annual shareholder meeting. Following this transaction, Barg directly holds 2,865 shares.
[Form 4] CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Insider Trading Activity
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. director Craig B. Thompson was granted 1,438 restricted stock units (RSUs) at $177.62 per share. This routine equity compensation increases his direct holdings to 3,851 shares. The RSUs vest on the earlier of May 8, 2027, or the business day before the company's next annual shareholder meeting, aligning his incentives with long-term shareholder interests.
[Form 4] CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Insider Trading Activity
A recent Form 4 filing indicates insider trading activity for Charles River Laboratories International, Inc. (CRL). Director Paul W. Graves acquired 1,438 shares of common stock at a price of $177.62 per share, totaling approximately $255,000. Following this transaction, Graves beneficially owns 2,384 shares of common stock directly.
Charles River (NYSE: CRL) investors approve 2026 incentive plan, pay and auditor
Shareholders of Charles River Laboratories International, Inc. (NYSE: CRL) approved the 2026 Long-Term Incentive Plan, ratified PricewaterhouseCoopers LLP as independent auditors for fiscal 2026, and gave advisory approval for named executive officer compensation at their annual meeting. Additionally, twelve directors were elected to serve until the 2027 annual meeting, with all proposals receiving majority shareholder support. These decisions, detailed in an 8-K filing, ensure continuity in governance and compensation strategies for the company.
Charles River Laboratories stock (US1591881009): Q1 earnings beat but FY2026 forecast cut
Charles River Laboratories (NYSE: CRL) reported Q1 2026 earnings that surpassed analyst estimates but subsequently lowered its full-year 2026 forecast, causing its stock to fall over 5% to $168.46 on May 12, 2026. Despite the shares dropping, Baird analyst Eric Coldwell maintained an Outperform rating and raised the price target to $213. The company, a key player in the contract research organization (CRO) sector, faces market headwinds but benefits from its strong position in providing essential services to the biopharma industry.
SomaLogic stock (US82489T1043): Completed $350M sale to Illumina
Standard BioTools has finalized the sale of its SomaLogic subsidiary to Illumina for $350 million on January 30, 2026. This transaction strengthens Standard BioTools' financial position and supports its strategic focus on proteomics and multiomics technologies. SomaLogic, known for its SomaScan platform, was a key asset in the deal, enhancing Illumina's multiomics portfolio.
Number of shareholders of Charles River Laboratories International, Inc. – HAM:RV6
This article provides details on the number of shareholders for Charles River Laboratories International, Inc. (HAM:RV6). It is presented on a financial platform, indicating market data and other financial tools are available for the company. The content appears to be a stub or a data placeholder rather than a full analytical report.
Charles River Laboratories International Inc (CRL) Stock Down 5.
Charles River Laboratories International Inc (CRL) stock fell 5.2% to $168.46, and GuruFocus's GF Value™ assessment indicates it is currently undervalued by 14.4%. With a GF Score™ of 79/100, CRL shows strong valuation and profitability but lower growth potential, and there has been no insider trading activity in the last three months. The current P/E ratio is significantly below its 5-year median, suggesting a potential entry point for investors.
Charles River Laboratories International Inc (CRL) Stock Down 5.2% -- Now Undervalued?
Charles River Laboratories International Inc (CRL) saw its stock fall by 5.2% to $168.46 on May 12, 2026. According to GuruFocus, the stock is considered "Modestly Undervalued" with a GF Value estimate of $196.69, indicating a potential margin of safety for investors. Despite strong valuation and profitability scores, its growth score is 4/10, and there has been no insider trading activity in the last three months.
Charles River (NYSE: CRL) director Abraham Ceesay receives 1,438-share stock grant
Charles River Laboratories (NYSE: CRL) director Abraham Ceesay received a grant of 1,438 shares of Common Stock at $177.62 per share on May 8, 2026. This award, a form of compensation, increased his direct holdings to 2,384 shares. The restricted stock units associated with this grant are set to vest on the earlier of May 8, 2027, or the business day prior to the company's next annual meeting of shareholders, aligning the award with continued service and future performance.
Charles River Labs (NYSE: CRL) director Martin Mackay receives new stock grants
Charles River Laboratories director Martin Mackay received two grants of common stock as part of his board compensation, totaling 2,845 shares at $177.62 per share. One grant was in lieu of director service fees for the term starting May 5, 2026. These restricted stock units are set to vest on the earlier of May 8, 2027, or the business day before the company’s next annual meeting of shareholders, with Mackay holding 17,137 shares directly after these transactions.
Director at Charles River (NYSE: CRL) gets 1,438-share equity grant
Nancy C. Andrews, a director at Charles River Laboratories (CRL), received an equity grant of 1,438 shares of common stock, valued at $177.62 per share. This compensation-related grant increased her direct holdings to 5,402 shares. The unvested restricted stock units are set to vest on the earlier of May 8, 2027, or the business day before the company's next annual meeting of shareholders.
Director at Charles River (NYSE: CRL) receives 1,973-share equity award
Charles River Laboratories International, Inc. director Reshema Kemps-Polanco was granted 1,973 restricted stock units (RSUs) on May 8, 2026, valued at $177.62 per share. These RSUs were awarded as part of routine compensation and vest upon the earlier of May 8, 2027, or the business day prior to the company’s next annual meeting, with one grant made in lieu of director service fees. This transaction indicates that part of the director's compensation is now equity-based rather than cash.
Charles River (CRL) Enhances Digital Pathology Platform for Faster Research
Charles River Laboratories International Inc (CRL) has announced significant advancements in its digital pathology platform, leveraging AI to enhance research efficiency and potentially reduce the need for animal testing. The company, a leading provider of drug discovery and development services, aims to shorten study durations and improve pathologist productivity. Despite insider selling activity, CRL holds a strong GF Score™ of 79/100, suggesting potential for long-term returns, though financial strength warrants careful consideration.
Charles River (CRL) Enhances Digital Pathology Platform for Faster Research
Charles River Laboratories International Inc (CRL) has announced significant advancements in its digital pathology platform, leveraging AI to enhance research efficiency and potentially reduce the need for animal testing. The company, a leading provider of drug discovery and development services, aims to shorten study durations and improve pathologist productivity through this innovative system. With a strong GF Score™ of 79, Charles River presents a compelling case for investors, despite mixed insider activity and moderate financial strength metrics that warrant careful consideration.
Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors
Charles River Laboratories International Inc. (CRL) stock fell by 5.16% to $168.46 on Monday, marking its fourth consecutive day of losses. This underperformance occurred during an otherwise positive trading session for the broader market, with the S&P 500 Index and the Dow Jones Industrial Average both seeing gains.
Charles River Laboratories stock (US1591881009): Core business and market position
Charles River Laboratories provides critical research services to biotech and pharma companies, offering drug discovery, safety assessment, and manufacturing support. The company operates as a contract research organization (CRO) with a business model focused on long-term contracts for early-stage drug development. Its key revenue drivers include preclinical services and cell/gene therapy CDMO, positioning it as a significant enabler for US biotech innovation.
Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow
Charles River Laboratories is accelerating its digital pathology platform with an AI-enabled end-to-end workflow to significantly reduce study timelines, improve pathologist efficiency, and support the reduction of animal use in nonclinical research. This initiative leverages AI for slide quality control and integrates digital primary pathology reviews, aiming to cut at least one week from standard pathology timelines. The company's approach is built on its extensive pathology expertise and robust data, ensuring regulatory readiness and advancing the 3Rs (replacement, reduction, and refinement of animal use).
A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Momentum
Charles River Laboratories International (CRL) has seen recent share price momentum, placing its stock near US$181. Valuation analyses offer conflicting views: one narrative suggests the stock is 42.1% undervalued with a fair value of $313.61, while Simply Wall St's DCF model indicates it might be overvalued at $140.41. Investors are encouraged to examine the underlying assumptions and risks of both models to form a balanced perspective on potential buying opportunities.
A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Momentum
Charles River Laboratories International (CRL) has seen recent share price momentum, bringing its stock to US$181. While one valuation narrative suggests the company is 42.1% undervalued with a fair value of $313.61, Simply Wall St's DCF model indicates the stock is overvalued at its current price. Investors are encouraged to review the underlying assumptions and risks before making investment decisions.
Leading Companies Enhancing Their Presence in the Tumor Models Market
The tumor models market is projected to reach $3.57 billion by 2030, growing at a CAGR of 10.8%, driven by advancements in organ-on-a-chip and 3D spheroid technologies, and rising investments in personalized oncology. Key players like WuXi AppTec and Charles River Laboratories are innovating, with a focus on tumor spheroid models to improve the accuracy of cancer research. The market segmentation includes various tumor types, applications, technologies, and end-users, highlighting the diverse landscape of this vital field.
Charles River Laboratories stock (US1591881009): Shares dip after recent run-up as analysts eye upsi
Shares of Charles River Laboratories (US1591881009) have pulled back after a significant monthly gain, currently trading around $187.93 on the NYSE. Despite this short-term dip, the stock remains up over the last year, reflecting sustained investor interest in the company's preclinical and clinical services. Analysts maintain an optimistic outlook, with average one-year price targets suggesting moderate to high upside potential, although organic revenue growth remains a concern.
Olin Corporation (NYSE:OLN) Q1 2026 Earnings Call Transcript
Olin Corporation discussed its Q1 2026 earnings, reporting that its epoxy business returned to profitability and Winchester commercial ammunition demand showed early growth. The company anticipates significantly improved Q2 earnings, projecting adjusted EBITDA between $160 million and $200 million, largely driven by pricing and volume improvements in its Chlor Alkali Products and Vinyls (CAPV) segment, despite an unplanned vinyls outage at its Freeport, Texas plant. Olin emphasizes its "value-first commercial approach" and structural cost reductions through its "Beyond two fifty" program, expecting these efforts to lead to strong cash generation and long-term shareholder value.
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors
Shares of Charles River Laboratories International Inc. (CRL) fell 2.23% on Friday, closing at $177.62. This underperformance occurred despite a generally positive trading session for the broader market, with both the S&P 500 Index and the Dow Jones Industrial Average posting gains. This marks the third consecutive day of losses for the stock.
These Analysts Increase Their Forecasts On Charles River After Better-Than-Expected Q1 Results
Charles River Laboratories reported better-than-expected Q1 earnings, with adjusted EPS of $2.06 against estimates of $1.94, and sales of $995.830 million exceeding expectations. Despite lowering its FY2026 guidance, CEO Birgit Girshick expressed confidence in improving results. Following the earnings, Evercore ISI Group and Barclays analysts maintained Outperform and Overweight ratings, respectively, while increasing their price targets for Charles River stock.
